Combination Therapy with Fidaxomicin and Hyalophora cecropia cecropins for Enteric Fever Treatment

Résumé

Salmonella enterica is a significant pathogen responsible for enteric fever worldwide. The rise of antibiotic-resistant strains has necessitated the search for alternative antibacterial agents. This study aimed to characterize S. enterica isolates and evaluate the antibacterial activity of fidaxomicin and cecropins against these isolates, alone and in combination. S. enterica isolates were characterized using cultural, morphological, and biochemical tests. Molecular identification was performed using 16S rRNA gene sequencing. The antibacterial activity of fidaxomicin and cecropins was assessed using the disc diffusion method. Three S. enterica subspecies enterica serovar Typhi strains CMSCT, R192829 and WGS1146 (STCM, STRL, and STWG) were identified, exhibiting characteristic cultural, morphological, and biochemical features. Fidaxomicin showed inhibition zones of 15.33-17.05 mm, while cecropins exhibited inhibition zones of 14.50-17.90 mm. The combination of fidaxomicin and cecropins (FID + CP) showed significantly higher inhibition zones (21.33-27.01 mm) compared to fidaxomicin and cecropins alone (p < 0.01). The study suggests that combining fidaxomicin with cecropins enhances antibacterial activity against S. enterica isolates, providing a potential therapeutic approach against enteric fever. This study generates insights into the antibacterial efficacy of fidaxomicin and cecropins against S. enterica, highlighting the potential of combination therapy to combat antibiotic resistance.

Citer ce document

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0